A combination therapy for cystic fibrosis
- PMID: 26406363
- PMCID: PMC4865247
- DOI: 10.1016/j.cell.2015.09.003
A combination therapy for cystic fibrosis
Abstract
The most prevalent form of cystic fibrosis arises from an amino acid deletion in the cystic fibrosis transmembrane conductance regulator, CFTR. A recently approved treatment for individuals homozygous for this mutation combines a chemical corrector, which helps CFTR fold, and a potentiator that increases CFTR channel activity.
Copyright © 2015 Elsevier Inc. All rights reserved.
Figures
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
